Join us for this exciting, live webinar led by Peter Merkel, MD, MPH. Dr. Merkel is the Chief of the Division of Rheumatology and Professor of Medicine and Epidemiology at the University of Pennsylvania. The webinar will focus on two drug studies for eosinophilic granulomatosis with polyangiitis (EGPA).
Dr. Sharon Chung, Professor of Clinical Medicine and Director at UCSF Vasculitis Clinic will give a patient-friendly overview of the role of genetics and the potential impact on vasculitis development.
Learn from and engage with medical professionals, researchers and patients. Topics include emerging therapies, living well with vasculitis, new medications, nutrition and more.
Our one-day, in-person vasculitis conferences feature engaging and informative presentations from medical experts and researchers as well as chances to connect with other people who, like you, get what it is like to live with vasculitis or love someone with vasculitis. Whether you are newly diagnosed with vasculitis or have been navigating a vasculitis diagnosis […]
Our one-day, in-person vasculitis conferences feature engaging and informative presentations from medical experts and researchers as well as chances to connect with other people who, like you, get what it is like to live with vasculitis or love someone with vasculitis. Whether you are newly diagnosed with vasculitis or have been navigating a vasculitis diagnosis […]
Our one-day, in-person vasculitis conferences feature engaging and informative presentations from medical experts and researchers as well as chances to connect with other people who, like you, get what it is like to live with vasculitis or love someone with vasculitis. Whether you are newly diagnosed with vasculitis or have been navigating a vasculitis diagnosis […]
​Just as the disease is unique for each person, so is the tracking of quality of life. Join us to learn about how to create a tool that works for you to track quality of life and disease impact. We will also talk about how to use this tool to more effectively communicate with your […]
EGPA now has a second treatment! Fasenra was approved in the fall of 2024 for EGPA and brings a new take on addressing the issues. Join this livestream to learn about the dual impact: IL-5 unique action and activating natural killer cells.Â
Get regular updates to your inbox.
